BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 14614004)

  • 1. HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin.
    Heinmöller P; Gross C; Beyser K; Schmidtgen C; Maass G; Pedrocchi M; Rüschoff J
    Clin Cancer Res; 2003 Nov; 9(14):5238-43. PubMed ID: 14614004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab.
    Dybdal N; Leiberman G; Anderson S; McCune B; Bajamonde A; Cohen RL; Mass RD; Sanders C; Press MF
    Breast Cancer Res Treat; 2005 Sep; 93(1):3-11. PubMed ID: 16184453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy.
    Hofmann M; Stoss O; Gaiser T; Kneitz H; Heinmöller P; Gutjahr T; Kaufmann M; Henkel T; Rüschoff J
    J Clin Pathol; 2008 Jan; 61(1):89-94. PubMed ID: 17412870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.
    Paik JH; Choe G; Kim H; Choe JY; Lee HJ; Lee CT; Lee JS; Jheon S; Chung JH
    J Thorac Oncol; 2011 Mar; 6(3):466-72. PubMed ID: 21258247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression.
    Kim H; Yoo SB; Choe JY; Paik JH; Xu X; Nitta H; Zhang W; Grogan TM; Lee CT; Jheon S; Chung JH
    J Thorac Oncol; 2011 Aug; 6(8):1359-66. PubMed ID: 21587085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histological tumor grade correlates with HER2/c-erB-2 status in invasive breast cancer: a comparative analysis between immunohistochemical (CB11 clone and Herceptest), FISH and differential PCR procedures.
    López-Guerrero JA; Navarro S; Noguera R; Almenar S; Pellin A; Vázquez C; Llombart-Bosch A
    Arkh Patol; 2003; 65(1):50-5. PubMed ID: 12669615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients.
    Al-Saad S; Al-Shibli K; Donnem T; Andersen S; Bremnes RM; Busund LT
    J Thorac Oncol; 2010 Oct; 5(10):1536-43. PubMed ID: 20802349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry.
    Pellegrini C; Falleni M; Marchetti A; Cassani B; Miozzo M; Buttitta F; Roncalli M; Coggi G; Bosari S
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3645-52. PubMed ID: 14506153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer.
    Lottner C; Schwarz S; Diermeier S; Hartmann A; Knuechel R; Hofstaedter F; Brockhoff G
    J Pathol; 2005 Apr; 205(5):577-84. PubMed ID: 15732132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER-2/neu expression in archival non-small cell lung carcinomas using FDA-approved Hercep test.
    Scheurle D; Jahanzeb M; Aronsohn RS; Watzek L; Narayanan R
    Anticancer Res; 2000; 20(3B):2091-6. PubMed ID: 10928158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances.
    Cabillic F; Gros A; Dugay F; Begueret H; Mesturoux L; Chiforeanu DC; Dufrenot L; Jauffret V; Dachary D; Corre R; Lespagnol A; Soler G; Dagher J; Catros V; Le Calve M; Merlio JP; Belaud-Rotureau MA
    J Thorac Oncol; 2014 Mar; 9(3):295-306. PubMed ID: 24518086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
    Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
    Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of HER2 overexpression in non-small cell lung cancer.
    Ugocsai K; Mándoky L; Tiszlavicz L; Molnár J
    Anticancer Res; 2005; 25(4):3061-6. PubMed ID: 16080566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and predictive value of HER2/neu oncogene in breast cancer.
    Masood S; Bui MM
    Microsc Res Tech; 2002 Oct; 59(2):102-8. PubMed ID: 12373720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 status in breast cancer determined by IHC and FISH: comparison of the results.
    Mrozkowiak A; Olszewski WP; Piaścik A; Olszewski WT
    Pol J Pathol; 2004; 55(4):165-71. PubMed ID: 15757204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients.
    Park HS; Lee JK; Kim DW; Kulig K; Kim TM; Lee SH; Jeon YK; Chung DH; Heo DS
    Lung Cancer; 2012 Aug; 77(2):288-92. PubMed ID: 22465695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non-small cell lung cancer.
    Nakamura H; Saji H; Ogata A; Hosaka M; Hagiwara M; Kawasaki N; Kato H
    Int J Cancer; 2003 Jan; 103(1):61-6. PubMed ID: 12455054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concordance between central and local laboratory HER2 testing from a community-based clinical study.
    Reddy JC; Reimann JD; Anderson SM; Klein PM
    Clin Breast Cancer; 2006 Jun; 7(2):153-7. PubMed ID: 16800975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy.
    Junker K; Stachetzki U; Rademacher D; Linder A; Macha HN; Heinecke A; Müller KM; Thomas M
    Lung Cancer; 2005 Apr; 48(1):59-67. PubMed ID: 15777971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concordant HER2 status between metastatic breast cancer cells in CSF and primary breast cancer tissue.
    Park IH; Kwon Y; Ro JY; Lee KS; Ro J
    Breast Cancer Res Treat; 2010 Aug; 123(1):125-8. PubMed ID: 19916047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.